Cell diameter measurements obtained with a handheld cell counter could be used as a surrogate marker of G2/M arrest and apoptosis in colon cancer cell lines exposed to SN-38

Biochemical and Biophysical Research Communications

Volumn 434, Issue 4, 2013, Pages 753-759

  Tahara, Makiko ^a,b   Inoue, Takeshi ^a   Miyakura, Yasuyuki ^b   Horie, Hisanaga ^b   Yasuda, Yoshikazu ^b   Fujii, Hirofumi ^b   Kotake, Kenjiro ^a   Sugano, Kokichi ^a  

^a TOCHIGI CANCER CENTER   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Apoptosis; Cell diameter; Colon cancer cell; G2 M arrest; Scepter 2.0 cell counter; SN 38

Indexed keywords

CELL NUCLEUS DNA; FIRTECAN; IRINOTECAN;

ACCURACY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL COUNT; CELL POPULATION; CELL PROLIFERATION; CELL SIZE; CELL STRAIN HT29; CELLULAR DISTRIBUTION; CHEMOSENSITIVITY; COLON CANCER; CONTROLLED STUDY; DISEASE MARKER; DNA CONTENT; DRUG EFFECT; DRUG EXPOSURE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; M PHASE CELL CYCLE CHECKPOINT; MEDICAL DEVICE; PRIORITY JOURNAL; REPRODUCIBILITY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CAMPTOTHECIN; CELL COUNT; CELL PROLIFERATION; CELL SIZE; CELL SURVIVAL; COLONIC NEOPLASMS; CYTOLOGICAL TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; G2 PHASE CELL CYCLE CHECKPOINTS; HCT116 CELLS; HT29 CELLS; HUMANS; MICROSCOPY, FLUORESCENCE; REPRODUCIBILITY OF RESULTS;

EID: 84878184502     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.03.128     Document Type: Article

References (20)

1. Puck T.T., Marcus P.I. Action of X-rays on mammalian cells. J. Exp. Med. 1956, 103:653-666.
2. Slater T.F. Studies on a succinate-neotetrazolium reductase system of rat liver. II. Points of coupling with the respiratory chain. Biochim. Biophys. Acta 1963, 77:365-382.
3. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65:55-63.
4. Allison D.C., Ridolpho P. Use of a trypan blue assay to measure the deoxyribonucleic acid content and radioactive labeling of viable cells. J. Histochem. Cytochem. 1980, 28:700-703.
5. Djordjevic B., Szybalski W. Genetics of human cell lines. III. Incorporation of 5-bromo- and 5-iododeoxyuridine into the deoxyribonucleic acid of human cells and its effect on radiation sensitivity. J. Exp. Med. 1960, 112:509-531.
6. Steck P.A., Voss P.G., Wang J.L. Growth control in cultured 3T3 fibroblasts. Assays of cell proliferation and demonstration of a growth inhibitory activity. J. Cell. Biol. 1979, 83:562-575.
7. Coward P., Wada H.G., Falk M.S., Chan S.D., Meng F., Akil H., Conklin B.R. Controlling signaling with a specifically designed Gi-coupled receptor. Proc. Natl. Acad. Sci. USA 1998, 95:352-357.
8. Cory A.H., Owen T.C., Barltrop J.A., Cory J.G. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun. 1991, 3:207-212.
9. Huang K.T., Chen Y.H. Inaccuracies in MTS assays: major distorting effects of medium, serum albumin, and fatty acids and fatty acids. Biotechniques 2004, 37. 406, 408, 410-412.
10. Ongena K., Das C., Smith J.L., Gil S., Johnston G. Determining cell number during cell culture using the Scepter cell counter. J. Vis. Exp. 2010, (45):e2204. 10.3791/2204.
11. Nitta K., Yokokura T., Sawada S., Kunimoto T., Tanaka T., Uehara N., Baba H., Takeuchi M., Miyasaka T., Mutai M. Antitumor activity of new derivatives of camptothecin. Gan To Kagaku Ryoho 1987, 14:850-857.
12. Kaneda N., Nagata H., Furuta T., Yokokura T. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res. 1990, 50:1715-1720.
13. Satoh T., Hosokawa M., Atsumi R., Suzuki W., Hakusui H., Nagai E. Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase. Biol. Pharm. Bull. 1994, 17:662-664.
14. te Poele R.H., Joel S.P. Schedule-dependent cytotoxicity of SN-38 in p53 wild-type and mutant colon adenocarcinoma cell lines. Br. J. Cancer 1999, 81:1285-1293.
15. Magrini R., Bhonde M.R., Hanski M.L., Notter M., Scherubl H., Boland C.R., Zeitz M., Hanski C. Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status. Int. J. Cancer 2002, 101:23-31.
16. Santisteban M.S., Montmasson M.P., Giroud F., Ronot X., Brugal G. Fluorescence image cytometry of nuclear DNA content versus chromatin pattern: a comparative study of ten fluorochromes. J. Histochem. Cytochem. 1992, 40:1789-1797.
17. Vermes I., Haanen C., Steffens-Nakken H., Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J. Immunol. Methods 1995, 184:39-51.
18. Deng G., Chen A., Hong J., Chae H.S., Kim Y.S. Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. Cancer Res. 1999, 59:2029-2033.
19. Jacob S., Aguado M., Fallik D., Praz F. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Cancer Res. 2001, 61:6555-6562.
20. Vilar E., Scaltriti M., Balmana J., Saura C., Guzman M., Arribas J., Baselga J., Tabernero J. Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines. Br. J. Cancer 2008, 99:1607-1612.